N-methyl amisulpride - LB pharmaceuticals
Alternative Names: LB 102; LB 102 LAI; LB-102 - LB PharmaceuticalsLatest Information Update: 09 Apr 2026
At a glance
- Originator LB Pharmaceuticals
- Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 7 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Schizophrenia
- Phase II Bipolar depression
Most Recent Events
- 27 Mar 2026 LB Pharmaceuticals plans a phase II trial for Major depressive disorders (Adjunctive treatment) in early 2027
- 25 Mar 2026 Phase-III clinical trials in Schizophrenia in USA (PO, Tablet) (NCT07363577)
- 25 Mar 2026 LB Pharmaceuticals plans to hold a pre-NDA meeting with the US FDA for Schizophrenia